SAN DIEGO--(

圣地亚哥--(

BUSINESS WIRE

商业热线

)--Certis Oncology Solutions, a precision oncology and translational science company, announced today that the United States Patent and Trademark Office (USPTO) has allowed a patent application directed to Certis’s predictive artificial intelligence/machine learning (AI/ML) platform, CertisAI™.

)--精密肿瘤学和转化科学公司Certis Oncology Solutions今天宣布，美国专利商标局（USPTO）已允许针对Certis预测人工智能/机器学习（AI/ML）平台CertisAI™的专利申请。

“The patent marks an important milestone for our company,” said Peter Ellman, President and CEO of Certis. “It substantiates the uniqueness of our proprietary platform and the underlying methods for predicting drug response,” he said. “By offering CertisAI as a service, we are democratizing access to powerful AI/ML tools, leveling the playing field for biopharmaceutical companies that may lack the internal resources required to build proprietary AI into their workflows.”.

Certis总裁兼首席执行官彼得·埃尔曼（PeterEllman）表示：“该专利标志着我们公司的一个重要里程碑。他说：“这证实了我们专有平台的独特性以及预测药物反应的基本方法。”。“通过提供CertisAI作为一项服务，我们正在民主化对强大AI/ML工具的访问，为可能缺乏将专有AI构建到其工作流程中所需的内部资源的生物制药公司提供公平的竞争环境。”。

The company launched CertisAI in April 2024 as an extension of its preclinical biopharmaceutical services offering. The platform brings data-driven precision to a variety of early development decisions and provides a virtual environment in which to test and validate hypotheses related to drug efficacy, resistance and synergies.

该公司于2024年4月推出CertisAI，作为其临床前生物制药服务的延伸。该平台为各种早期开发决策带来了数据驱动的精确度，并提供了一个虚拟环境，用于测试和验证与药物功效，耐药性和协同作用相关的假设。

By correlating drug features and drug response with gene expression signatures, CertisAI can optimize preclinical model selection for drug efficacy studies and inform patient enrollment criteria for clinical trials—commonly cited causes of failed development programs. In silico analyses also can inform regulatory strategies, including label expansion and drug repurposing..

通过将药物特征和药物反应与基因表达特征相关联，CertisAI可以优化药物疗效研究的临床前模型选择，并为临床试验的患者入选标准提供信息，这些临床试验通常是开发计划失败的原因。计算机分析还可以为监管策略提供信息，包括标签扩展和药物再利用。。

The patent broadly protects a predictive AI/ML platform that integrates multiple data sets including drug features, gene expression biomarkers, and drug response, as well as the use of patient-derived xenograft (PDX) for model validation. The patent protection is expected to last until March 2043.

该专利广泛保护了预测性AI/ML平台，该平台集成了多个数据集，包括药物特征，基因表达生物标志物和药物反应，以及使用患者衍生的异种移植物（PDX）进行模型验证。专利保护预计将持续到2043年3月。

About CertisAI™

关于CertisAI™

CertisAI™ is a patented predictive artificial intelligence/machine learning (AI/ML) platform developed by Certis Oncology Solutions. It is the first and only commercially available, validated AI/ML platform that predicts therapeutic efficacy by identifying complex gene expression signatures that correlate with drug response.

CertisAI™是由Certis Oncology Solutions开发的专利预测人工智能/机器学习（AI/ML）平台。它是第一个也是唯一一个商业上可用的，经过验证的AI/ML平台，通过识别与药物反应相关的复杂基因表达特征来预测治疗效果。

The platform is designed to assist pharmaceutical researchers to develop and clinicians to identify new treatment options for specific cancers based on a tumor’s unique gene expression profile..

该平台旨在帮助药物研究人员开发和临床医生根据肿瘤独特的基因表达谱确定特定癌症的新治疗选择。。

About Certis Oncology Solutions

Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. The company’s product is Oncology Intelligence® — highly predictive therapeutic response data derived from advanced models of cancer. We partner with physician-scientists and industry researchers to expand access to precision oncology and close the problematic translation gap between preclinical studies and clinical trials..

Certis Oncology Solutions是一家致力于实现精准肿瘤学承诺的生命科学技术公司。该公司的产品是Oncology Intelligence®，它是从先进的癌症模型中获得的高度预测性治疗反应数据。我们与医生科学家和行业研究人员合作，扩大精准肿瘤学的使用范围，缩小临床前研究和临床试验之间存在问题的翻译差距。。

Since its founding in 2016, Certis has offered

自2016年成立以来，Certis一直提供

personalized functional testing

个性化功能测试

to help inform individual cancer treatment decisions, an approach advocated by cancer researchers and oncology clinicians worldwide. Using our patented

帮助告知个人癌症治疗决策，这是全球癌症研究人员和肿瘤临床医生倡导的一种方法。使用我们的专利

artificial intelligence/machine learning platform

人工智能/机器学习平台

and more clinically relevant,

更具临床相关性，

patient-derived tumor models

患者来源的肿瘤模型

, we bring certainty to drug development decisions and help secure clear and compelling evidence of drug efficacy. Certis operates a CLIA-certified, AAALAC- and OLAW-accredited laboratory in Sorrento Valley, the heart of San Diego’s life sciences industry.

，我们为药物开发决策带来确定性，并帮助获得明确而令人信服的药物疗效证据。Certis在圣地亚哥生命科学产业的中心Sorrento Valley经营着一家经CLIA认证、AAALAC和OLAW认证的实验室。

For more information about Certis, visit

有关证书的更多信息，请访问

www.certisoncology.com

www.certisoncology.com

.

.